Coherus BioSciences Gets FDA Approval for Loqtorzi, Chemotherapy Combination
October 27 2023 - 4:09PM
Dow Jones News
By Sabela Ojea
Coherus BioSciences and Shanghai Junshi Biosciences said the
U.S. Food and Drug Administration approved its Loqtorzi antibody to
treat nasopharyngeal cancer when used with chemotherapy.
The biotechnology companies said Loqtorzi said is aimed at
patients with metastatic nasopharyngeal cancer.
The FDA backed Loqtorzi in combination with chemotherapy drugs
cisplatin and gemcitabine.
Loqtorzi is expected to be available in the U.S. in the first
quarter of 2024.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 27, 2023 15:54 ET (19:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jul 2023 to Jul 2024